Global Drug Abuse Treatment Market, By Abuse Type (Alcohol Dependence, Tobacco/Nicotine Addiction, and Opioid Addiction), By Drug Type (Disulfiram, Acamprosate, Naltrexone, Methadone, Buprenorphine, Nicotine Addiction Treatment ((Nicotine Replacement Treatment (Nicotine Patch, Nicotine Gum, Nicotine Lozenge, Nicotine Spray, Nicotine Inhaler)) ((Non-Nicotine Medication, (Bupropion, and Varenicline)), and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 20.70 Bn in 2023 and is expected to exhibit a CAGR of 8.1% during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
The rising abuse of drugs and alcohol globally has significantly fueled the growth of the drug abuse treatment market in recent years. With growing substance dependency issues, more people are seeking medical and clinical help to overcome addiction. According to the World Drug Report 2021 published by the United Nations Office on Drugs and Crime, around 275 million people worldwide used drugs in 2020, with around 36 million struggling with drug use disorders.
Global Drug Abuse Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others, faced problems with regard to the transportation of drugs from one place to another.
COVID-19 had a positive impact on the global drug abuse treatment market, attributed to the increase in spread of covid-19 infection. For instance, according to an article published in Discoveries by the University of Texas Health Science, the U.S. states that the COVID-19 pandemic has had a dramatic effect on the prevalence of Substance Use Disorder (SUDs) and treatment options for persons seeking healthcare for acute health complications. Since the onset of COVID-19, there has been a 23% increase in alcohol abuse and a 16% increase in drug abuse for people who had consumed those substances before the pandemic.
Global Drug Abuse Treatment Market: Key Developments
Increasing inorganic growth strategies such as partership are expected to aid in the growth of the global drug abuse treatment market. For instance, on March 29, 2023, Emergent BioSolutions Inc. recieved U.S. Food and Drug Administration (FDA) approval for NARCAN Naloxone HCl Nasal Spray 4 mg as an over-the-counter (OTC) for emergency treatment of opioid overdose. NARCAN Nasal Spray is an OTC treatment, used to access it without a prescription that is used to reduce the number of opioid overdose deaths.
Browse 24 Market Data Tables and 28 Figures spread through 160 Pages and in-depth TOC on “Global Drug Abuse Treatment Market”- Forecast to 2030, Global Drug Abuse Treatment Market, By Abuse Type (Alcohol Dependence, Tobacco/Nicotine Addiction, and Opioid Addiction), By Drug Type (Disulfiram, Acamprosate, Naltrexone, Methadone, Buprenorphine, Nicotine Addiction Treatment ((Nicotine Replacement Treatment (Nicotine Patch, Nicotine Gum, Nicotine Lozenge, Nicotine Spray, Nicotine Inhaler)) ((Non-Nicotine Medication, (Bupropion, and Varenicline)), and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/drug-abuse-treatment-market-2011
Key Takeaways of the Global Drug Abuse Treatment Market:
- The global drug abuse treatment market is expected to exhibit a CAGR of 8.1% during the forecast period due to the rising number of organ transplant procedures across the globe. For instance, according to the data published by the American Transplant Foundation in 2022, over 41,000 organ transplant procedures were completed in the U.S. in the year 2020 alone. The rising number of organ transplant procedures across the globe is a key factor driving the growth of the global drug abuse treatment market.
- Among abuse type, the opioid addiction segment is estimated to hold a dominant position in the global drug abuse treatment market over the forecast period. For instance, on May 22, 2023, Indivior PLC a pharmaceutical company received S. Food and Drug Administration (FDA)-approved OPVEE (nalmefene) nasal spray for the emergency treatment of known or suspected opioid overdoses induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older.
- Among region, North America is expected to be the dominant region in the global drug abuse treatment market, owing to increasing alcohol consumption in the region, which is expected to drive segment growth over the forecast period. For instance, in 2021, the (National Institute on Alcohol Abuse and Alcoholism) NIAAA reports that approximately 38.4% of individuals 18–24 years old drank alcohol in the past month, with 26.9% engaging in binge drinking. Most alcoholics and those suffering from alcohol use disorder seek treatment options due to legal, financial, health, work, or family problems caused by excessive drinking.
- Major players operating in the global drug abuse treatment market include Cipla Limited, Glenmark Pharmaceuticals, Pfizer Inc., Mylan N.V., Odyssey Pharmaceuticals Inc., Lil' Drug Store Products Inc., Indivior Plc., Dr. Reddy's Laboratories, Teva Pharmaceutical Industries Ltd., British American Tobacco Plc., Alkermes, Sun Pharmaceuticals, BioCorRx, Inc., DXC Technology Company, and GenoLogics.
